Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain (PPP-Care)

University Hospital, Rouen

Status: Completed

Conditions: Opioid Use; Non-cancerous Pain

Treatments: Behavioral: Admission conciliation interview; Behavioral: Targeted pharmaceutical interview; Behavioral: Discharge conciliation interview

Study type: Interventional

Funder types: Other

Identifiers

NCT05196386

2019/0025/HP

Details and patient eligibility

About

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Enrollment: 100 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 and < 75 years old when entering the rheumatology department
• Hospitalization in the rheumatology department
• Patient with acute non-traumatic musculoskeletal disease
• Patient not taking grade III opioid treatment
• Patient affiliated to a social security scheme
• Patient having read and understood the information letter and signed the consent form
• Patient present on a day which the pharmacy intern is present

Exclusion criteria

• Presence of cancer, fibromyalgia, already diagnosed at inclusion
• Patient does not understand French
• Patient with Current or past opioid addiction
• Person deprived of liberty by administrative or judicial decision

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Patient with targeted pharmaceutical interview

Experimental group

Description:

Specific information about treatment delivered by pharmacist

Treatment:

Behavioral: Discharge conciliation interview

Behavioral: Targeted pharmaceutical interview

Behavioral: Admission conciliation interview

Patient without targeted pharmaceutical interview

Other group

Description:

No Specific information about treatment delivered by pharmacist

Treatment:

Behavioral: Discharge conciliation interview

Behavioral: Admission conciliation interview